- 101. Erythema due to burn [first degree] of lower limb(s)
- [ ] (UMLS (ICD9CM) C0161270) =Injury or Poisoning
| - 124. erythrocyte membrane
- [semipermeable outer portion of the red corpuscle; known as a 'ghost' after hemolysis. ( CSP )] (UMLS (CSP) C0014780) =Cell Component ;
=cell membrane;
|
- 102. Erythema due to burn [first degree] of trunk
- [ ] (UMLS (ICD9CM) C0161107) =Injury or Poisoning
| - 125. Erythrocytes
- (UMLS (HL7) C1546761) =Intellectual Product =Specimen Source Codes;
|
- 103. Erythema due to burn [first degree] of upper limb, except wrist and hand
- [ ] (UMLS (ICD9CM) C0161156) =Injury or Poisoning
| - 126. Erythrocytes
- (UMLS (HL7) C1550635) =Body Substance =SpecimenEntityType;
|
- 104. Erythema due to burn [first degree] of wrist(s) and hand(s)
- [ ] (UMLS (ICD9CM) C0161211) =Injury or Poisoning
| - 127. Erythrocytic Cast Formation
- (UMLS (NCI) C1333437) =Finding
|
- 105. ERYTHEMA INFECTIOSUM
- [Contagious infection with human B19 Parvovirus most commonly seen in school age children and characterized by fever, headache, and rashes of the face, trunk, and extremities. It is often confused with rubella. ( MSH )] (UMLS (ICD9CM) C0085273) =Disease or Syndrome ;
=erythema;
Skin Diseases, Viral;
Parvoviridae Infections;
| - 128. Erythrocytophagy
- [Erythrophagocytosis; phagocytosis of erythrocytes. ( NCI )] (UMLS (NCI) C0302486) =Finding
|
- 106. erythema multiforme
- [skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic bull's-eye lesions usually occurring on the dorsal aspect of the hands and forearms. ( CSP )] (UMLS (CSP) C0014742) =Disease or Syndrome =Skin Diseases, Vesiculobullous;
erythema =Erythema Multiforme Major | - 129. erythrodermia
- [ ] (UMLS (CSP) C0598398) =Disease or Syndrome
|
- 107. Erythema Multiforme Major
- [A variant of bullous erythema multiforme. It ranges from mild skin and mucous membrane lesions to a severe, sometimes fatal systemic disorder. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis, and sometimes blindness. The cause of the disease is unknown. ( MSH )] (UMLS (NCI) C0038325) =Disease or Syndrome ;
=erythema multiforme;
stomatitis | - 130. Erythroid Hyperplasia
- (UMLS (NCI) C0014800) =Disease or Syndrome ;
|
- 108. Erythema Multiforme Minor
- [Self-limiting form of Erythema Multiforme. ( NCI )] (UMLS (NCI) C0857751) =Disease or Syndrome
| - 131. Erythroid Neoplasm
- (UMLS (NCI) C1333438) Erythroid Tumor =Neoplastic Process
|
- 109. ERYTHEMA NODOS TB-UNSPEC
- (UMLS (ICD9CM) C0014744) =Disease or Syndrome
| - 132. Erythroid Precursors 50 Percent or More of Bone Marrow Nucleated Cells
- (UMLS (NCI) C1333439) Erythroid Precursors 50% or More of Bone Marrow Nucleated Cells =Laboratory or Test Result
|
- 110. erythema nodosum
- [erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are usually tender, multiple, and bilateral; these nodules are located predominantly on the shins with less common occurrence on the thighs and forearms; they undergo characteristic color changes ending in temporary bruise-like areas; this condition usually subsides in 3-6 weeks without scarring or atrophy. ( CSP )] (UMLS (CSP) C0014743) =Disease or Syndrome =dermatitis medicamentosa;
erythema =Sweet's Syndrome | - 133. Erythroid Precursors 80 Percent or More of Bone Marrow Nucleated Cells
- (UMLS (NCI) C1333440) Erythroid Precursors 80% or More of Bone Marrow Nucleated Cells =Laboratory or Test Result
|
- 111. Erythematosquamous dermatosis
- (UMLS (ICD9CM) C0014747) =Disease or Syndrome
| - 134. Erythroid Progenitor Cell
- [erythroid stem cells derived from myeloid stem cells; the progenitor cells develop in two phases, erythroid burst-forming units (bfu-e) followed by erythroid colony-forming units (cfu-e); bfu-e differentiate into cfu-e on stimulation by erythropoietin, and then further differentiate into erythroblasts when stimulated by other factors. ( CSP )] (UMLS (NCI) C0014802) =Cell ;
=hematopoietic stem cell;
|
- 112. ERYTHEMATOUS COND NEC
- [ ] (UMLS (ICD9CM) C1963173) Other specified erythematous conditions;
=Disease or Syndrome | - 135. erythroidine
- [ ] (UMLS (CSP) C0178624) =Organic Chemical; Pharmacologic Substance ;
|
- 113. ERYTHMTSQUAMOUS DERM NEC
- [ ] (UMLS (ICD9CM) C0375481) =Disease or Syndrome
| - 136. Erythroleukemia in Remission
- [Erythroleukemia that is responding to therapy, i.e. It is not progressing and possibly regressing. ( NCI )] (UMLS (NCI) C0686601) =Neoplastic Process
|
- 114. erythrina alkaloid
- [ ] (UMLS (CSP) C0598685) =Organic Chemical
| - 137. ERYTHROMELALGIA
- [A peripheral arterial disease that is characterized by the triad of ERYTHEMA, burning PAIN, and increased SKIN TEMPERATURE of the extremities (or red, painful extremities). Erythromelalgia may be classified as primary or idiopathic, familial or non-familial. Secondary erythromelalgia is associated with other diseases, the most common being MYELOPROLIFERATIVE DISORDERS. ( MSH )] (UMLS (ICD9CM) C0014804) =Disease or Syndrome ;
=blood vessel disorder;
|
- 115. Erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl Alcohol Hydrochloride
- [The hydrochloride salt form of ritodrine, a phenethylamine derivative with tocolytic activity. Ritodrine hydrochloride binds to and activates beta-2 adrenergic receptors of myocytes in the uterine myometrium, which results in decreased intensity and frequency of uterine contraction. Specifically, ritodrine hydrochloride probably activates adenyl cyclase, thereby increasing production of cyclic adenosine monophosphate (cAMP), which in turn enhancing the efflux of calcium from vascular smooth muscle cells. A lack of intracellular calcium prevents uterine myometrial contraction. In addition, this agent may directly inactivate myosin light chain kinase, a critical enzyme necessary for the initiation of muscle contractions. ( NCI )] (UMLS (NCI) C0356649) =Organic Chemical; Pharmacologic Substance =RITODRINE;
=RITODRINE HYDROCHLORIDE 10 MG/ML;
RITODRINE HYDROCHLORIDE 15 MG/ML;
RITODRINE HYDROCHLORIDE 10 MG | - 138. ERYTHROMYCIN
- [bacteriostatic antibiotic macrolide produced by Streptomyces erythreus; in sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits; this binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. ( CSP )] (UMLS (NCI) C0014806) =Organic Chemical; Antibiotic =macrolide antibiotic;
[AM200] ERYTHROMYCINS/MACROLIDES;
[DE752] ANTIACNE AGENTS, TOPICAL;
[OP201] ANTIBACTERIALS, TOPICAL OPHTHALMIC =ERYTHROMYCIN ESTOLATE;
ERYTHROMYCIN ETHYLSUCCINATE;
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[(3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentad;
6-O-Methylerythromycin;
Dirithromycin;
ERYTHROMYCIN GLUCEPTATE;
ERYTHROMYCIN LACTOBIONATE;
ERYTHROMYCIN STEARATE;
ERYTHROMYCIN ESTOLATE;
ERYTHROMYCIN ETHYLSUCCINATE;
ERYTHROMYCIN GLUCEPTATE;
ERYTHROMYCIN LACTOBIONATE;
ERYTHROMYCIN STEARATE;
ERYTHROMYCIN BASE MISC. POWDER (GM);
ERYTHROMYCIN 125 MG;
ERYTHROMYCIN 333 MG;
ERYTHROMYCIN 125 MG/5ML;
ERYTHROMYCIN 250 MG;
ERYTHROMYCIN 500 MG;
ERYTHROMYCIN 0.5 %;
ERYTHROMYCIN 3 %;
ERYTHROMYCIN 1.5 %;
ERYTHROMYCIN 2 % |
- 116. erythroblast
- [Immature, nucleated erythrocytes occupying the stage of erythropoiesis that follows formation of erythroid progenitor cells and precedes formation of reticulocytes. Popularly called normoblasts. (MeSH) ( NCI )] (UMLS (CSP) C0014762) =Cell
| - 139. ERYTHROMYCIN ESTOLATE
- [The lauryl sulfate ester of propionyl erythromycin, a broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin estolate diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin estolate may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved. ( NCI )] (UMLS (NCI) C0014809) =Organic Chemical; Antibiotic =ERYTHROMYCIN;
=ERYTHROMYCIN ESTOLATE 250 MG;
ERYTHROMYCIN ESTOLATE 250 MG/5ML;
ERYTHROMYCIN ESTOLATE 500 MG;
ERYTHROMYCIN ESTOLATE 125 MG;
ERYTHROMYCIN ESTOLATE 125 MG/5ML;
ERYTHROMYCIN ESTOLATE 100 MG/ML |
- 117. erythroblastosis fetalis
- [hemolytic anemia of the fetus or newborn caused by transplacental transmission of maternally formed antibody, usually secondary to an incompatibility between the blood groups of mother and offspring. ( CSP )] (UMLS (CSP) C0014761) =Disease or Syndrome =blood group incompatibility;
embryo/fetus disorder;
Infant, Newborn, Diseases;
perinatal blood group incompatibility =Hydrops Fetalis;
bilirubin encephalopathy;
| - 140. ERYTHROMYCIN ETHYLSUCCINATE
- [The ethylsuccinate salt form of erythromycin, a broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin ethylsuccinate diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin ethylsuccinate may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved. ( NCI )] (UMLS (NCI) C0014810) =Organic Chemical; Antibiotic =ERYTHROMYCIN;
=Erythromycin ethylsuccinate 100 mg/2.5mL;
ERYTHROMYCIN ETHYLSUCCINATE 40 MG/ML;
ERYTHROMYCIN ETHYLSUCCINATE 200 MG/5ML;
ERYTHROMYCIN ETHYLSUCCINATE 400 MG/5ML;
ERYTHROMYCIN ETHYLSUCCINATE 200 MG;
ERYTHROMYCIN ETHYLSUCCINATE 400 MG |
- 118. Erythrocebus
- [a genus of Old World monkeys of the family CERCOPITHECINAE that inhabit the forests and savannas of Africa. It contains only one species, ERYTHROCEBUS PATAS, also known as the patas monkey or red monkey. ( MSH )] (UMLS (CSP) C0085230) =Mammal
| - 141. ERYTHROMYCIN LACTOBIONATE
- [The lactobionate salt form of erythromycin, a broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin lactobionate diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin lactobionate may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved. ( NCI )] (UMLS (NCI) C0059562) =Organic Chemical; Antibiotic ;
=ERYTHROMYCIN;
=ERYTHROMYCIN LACTOBIONATE 1 GM/VIL;
ERYTHROMYCIN LACTOBIONATE 50 MG/ML;
ERYTHROMYCIN LACTOBIONATE 500 MG;
ERYTHROMYCIN LACTOBIONATE 1 GM |
- 119. erythrocyte
- [red blood cells; mature erythrocytes are non-nucleated, biconcave disks containing hemoglobin whose function is to transport oxygen. ( CSP )] (UMLS (CSP) C0014792) =Cell ;
=blood cell;
Body Part =Polychromatophilic Erythrocyte | - 142. ERYTHROMYCIN STEARATE
- [The stearate salt form of erythromycin, a broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin stearate diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin stearate may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved. ( NCI )] (UMLS (NCI) C0059566) =Organic Chemical; Antibiotic ;
=ERYTHROMYCIN;
=ERYTHROMYCIN STEARATE 250 MG;
ERYTHROMYCIN STEARATE 500 MG |
- 120. Erythrocyte Colony Stimulating Factor
- [A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo). Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04) ( NCI )] (UMLS (NCI) C0376541) =Amino Acid, Peptide, or Protein; Pharmacologic Substance =ECSF;
Recombinant Protein =EPO | - 143. erythroplakia
- [(eh-RITH-ro-PLAY-kee-a) A reddened patch with a velvety surface found in the mouth. ( NCI )] (UMLS (NCI) C0014818) =Disease or Syndrome ;
=Precancerous Condition;
|
- 121. erythrocyte count
- [number of red blood cells per unit volume in a sample of venous blood. ( CSP )] (UMLS (CSP) C0014772) =Laboratory Procedure ;
=blood cell count;
| - 144. erythropoiesis
- [production of red blood cells. ( CSP )] (UMLS (CSP) C0014819) =Organ or Tissue Function ;
=hematopoiesis;
|
- 122. Erythrocyte Distribution Width Measurement
- [An index of the variation in the size of the red cells and can be used to detect subtle degress of anisocytosis. It is computed directly from the RBC histogram and is calculated as a standard statictical value, the coefficient of variation of the red cell volume ditribution (ratio of standard deviation and mean copuscular volume). ( NCI )] (UMLS (NCI) C0427460) =Laboratory Procedure
| - 145. erythropoiesis inhibitor
- [ ] (UMLS (CSP) C0598399) =Chemical Viewed Functionally
|
- 123. erythrocyte ghost
- [ ] (UMLS (CSP) C0014776) =Cell Component ;
| - 146. erythropoietic protoporphyria porphyria
- [ ] (UMLS (CSP) C0599230) =Disease or Syndrome
|
home
